(Q36673680)

English

Randomized Phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-escaped metastatic prostate cancer

scientific article published on January 2004

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Randomized Phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-escaped metastatic prostate cancer (English)

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

Simon Horenblas

3

object named as

S Horenblas

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

author name string

W Albrecht

1

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

H Van Poppel

2

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

G Mickisch

4

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

A Horwich

5

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

V Serretta

6

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

G Casetta

7

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

J M Maréchal

8

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

W G Jones

9

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

S Kalman

10

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

R Sylvester

11

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

language of work or name

0 references

publication date

1 January 2004

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

British Journal of Cancer

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

90

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

1

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

100-105

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Estramustine and vinblastine for patients with progressive androgen-independent adenocarcinoma of the prostate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395315

30 September 2017

Preliminary evaluation of a short course of estramustine phosphate and docetaxel (Taxotere) in the treatment of hormone-refractory prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395315

30 September 2017

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395315

30 September 2017

Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395315

30 September 2017

Mechanisms of action and clinical uses of estramustine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395315

30 September 2017

The present role of estramustine phosphate in advanced prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395315

30 September 2017

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395315

30 September 2017

The assessment of treatment outcomes in metastatic prostate cancer: Changing endpoints

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395315

28 June 2018

Continuous infusion of vinblastine for advanced hormone-refractory prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395315

28 June 2018

Antiinvasive activity of estramustine on malignant MO4 mouse cells and on DU-145 human prostate carcinoma cells in vitro.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395315

28 June 2018

Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395315

28 June 2018

Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395315

28 June 2018

Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395315

20 September 2018

Mitomycin C versus estramustine in the treatment of hormone resistant metastatic prostate cancer: the final analysis of the European Organization for Research and Treatment of Cancer, genitourinary group prospective randomized phase III study (30865

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395315

20 September 2018

Estramustine Phosphate Sodium

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6601468

21 January 2018

Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/14710214

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/14710214

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of cancer and leukemia group B Trial 9780

1 reference

https://pubmed.ncbi.nlm.nih.gov/14710214

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trimetrexate in prostatic cancer: preliminary observations on the use of prostate-specific antigen and acid phosphatase as a marker in measurable hormone-refractory disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/14710214

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quantifying the amount of variation in survival explained by prostate-specific antigen

1 reference

https://pubmed.ncbi.nlm.nih.gov/14710214

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/14710214

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/14710214

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A pharmacokinetically guided Phase II study of carboxyamido-triazole in androgen-independent prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/14710214

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/SJ.BJC.6601468

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36673680&oldid=2264599081"